Showing 1199 Results
NPC responds to CMS's Information Collection Request on the Negotiation Data Elements and Drug Price Negotiation Process for the Initial Price Applicability Year 2027
NPC offered the agency insights on the data collection requirements it has proposed to inform the second round of the the price-setting efforts in the Medicare Drug Price Negotiation Program.
The Accelerated Approval Program for Oncology Drugs: Celebrating More Than 250,000 Life-Years Gained and Counting
NPC’s commentary in AJMC examines evidence regarding the clinical benefit of the FDA’s Accelerated Approval Program and finds it is working for patients.
Analyzing Accelerated Approval for Oncology Drugs: NPC Commentary Evaluates Evidence on FDA Program Effectiveness, Concludes Benefits Outweigh Risks
A new publication in AJMC examines evidence regarding the clinical benefit of the FDA’s Accelerated Approval Program and finds it is working for patients
NPC Submits Comments on Next Steps in the 21st Century Cures Initiative
NPC's comments respond to a Congressional Request for Information soliciting input on opportunities to build on the 21st Century Cures Act.
New Study Sheds Light on Rebate Guarantees and the Role of Employer Benefits Consultants and Brokers in PBM Selection
NPC research published in the American Journal of Managed Care underscores the role employer benefits consultants may play in perpetuating employer reliance on guaranteed rebate arrangements.
Prescription Rebate Guarantees: Employer Insights
Nearly two-thirds of employer drug benefit decision makers reported having rebate agreements with a rebate guarantee for specialty drugs, according to new research from NPC published in the American…
NPC Submits Comments to CMS on Draft Guidance for the Medicare Drug Price Negotiation Program for 2027
In this comment letter, NPC weighs in on CMS' s draft guidance regarding the second cycle of the Medicare Drug Price Negotiation Program.
New Primer Highlights Unanswered Questions and Unintended Consequences of State Prescription Drug Affordability Boards
Four states have given these boards authority to set drug prices. A new Health Affairs Forefront publication highlights the uncertainties, challenges, and unintended consequences for patients amid…
Unanswered Questions and Unintended Consequences of State Prescription Drug Affordability Boards
Four states have given these boards authority to set drug prices. Published in Health Affairs Forefront, this primer highlights the uncertainties, challenges, and unintended consequences for patients…
NPC's John O'Brien Delivers 2024 Hooding Ceremony Address at Washington State University
Dr. John M. O'Brien spoke to graduates of Washington State University's College of Pharmacy and Pharmaceutical Sciences at the hooding ceremony on Thursday, May 9, 2024.
Acknowledging the Challenges in Gene Therapy: Perspectives on ICER's White Paper
The ICER/NEWDIGS white paper identifies market solutions and policy reforms to mitigate the challenges of paying for gene therapies. In this analysis, NPC summarizes the key takeaways and note a few…